Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-26-Q-9304

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Texas, UNITED STATES

SourceSAM
The Department of Defense, through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-26-Q-9304) for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) as part of its ongoing efforts to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). This initiative is mandated by 10 U.S.C. § 1074g and further detailed in 32 CFR Section 199.21, which require the Department of War (DoW) to evaluate pharmaceutical agents for inclusion in the Uniform Formulary (UF) based on clinical and cost effectiveness. The scope of this procurement encompasses the acquisition of pharmaceutical agents within specific drug classes identified for potential placement on the UF. The process is guided by recommendations from the DoW Pharmacy and Therapeutics (P&T) Committee, which will review newly approved drugs during its August 2026 meeting. The drugs under consideration include: - Atoncy (ADHD Agents, Non-stimulants) - Baxfendy (Diuretics, Mineralocorticoid Receptor Antagonists) - Duloxetine (Antidepressants and Non-opioid Pain Syndrome Agents, SNRI) - Filkri (White Blood Cell Stimulants, Filgrastims; ADP eligible only due to non-TAA compliance) - Hepcludex (Hepatitis D Agent) - Lynavoy (Gastrointestinal-2 Agents) - Veppanu (Breast Cancer Agents, Estrogen Receptor Antagonist) - Xocova (Antivirals, FDA Approved COVID Therapeutics) - Xtoro (Antibiotics, Quinolones) The intended outcome of this procurement is to secure competitive pricing and additional discounts for pharmaceutical agents selected for the UF, thereby optimizing cost-sharing arrangements and ensuring access to clinically effective medications for MHS beneficiaries. The solicitation includes detailed instructions, deadlines, and points of contact, all outlined in the attached RFQ (HT9402-26-Q-9304). Contractors are expected to submit responses to clinical questions via email to the designated points of contact by the specified deadline. A pre-quotation teleconference is scheduled for July 15, 2026, with further details provided in Part 2.4 of the RFQ. Interested parties should review the appendices related to UF BPA and UF ADP, and adhere to submission requirements as described in the solicitation documents. Key requirements for participation include the ability to manufacture pharmaceutical preparations (NAICS Code: 325412, Pharmaceutical Preparation Manufacturing), and compliance with relevant federal regulations. The place of performance is Texas, United States. The primary contracting entity is the Defense Health Agency, a federal office under the Department of Defense. For further information or clarification, contractors may contact: - Stephanie Erpelding (Primary Contact): [email protected] - Julianne Canaley (Secondary Contact): dha.san-antonio-tx.acquis-procure.mbx.pharmacy-support@health.mil The solicitation is currently active, with a response deadline of July 27, 2026, at 17:07. Additional details, including attachments and instructions, are available via the official notice on SAM.gov (Opportunity ID: 92aa36a7b05249afba4ee120314edc11). Contractors specializing in pharmaceutical manufacturing and distribution, particularly those with experience in federal healthcare procurement and formulary management, are encouraged to review the RFQ and consider participation in this opportunity to support the Military Health System’s pharmacy benefits program.
Documents14